Alvotech Makes Multiple Moves As It Allies With Advanz For Five European Biosimilars
Firm Also Drops Products From Stada Deal And Reveals A Pair Of New Pipeline Products
• By David Wallace
Generate a summary of this article
Listen to this article
In a busy week for Alvotech, the firm has announced an expansion of its partnership with Advanz to cover five further European biosimilars, at the same time as revealing two new pipeline assets. Meanwhile, the company has also dropped three products from an existing European partnership with Stada and has also terminated a development deal with BiosanaPharma.
The deal with Advanz covers five biosimilars in Europe • Source: Shutterstock
Key Takeaways
Alvotech and Advanz have partnered to commercialize five proposed biosimilars in Europe
Alvotech has announced a five-product biosimilar commercialization deal with Advanz Pharma in Europe, capping a busy week that has also seen the biosimilars developer make a number of other key disclosures relating to its pipeline and partnerships.
One of these involved revealing biosimilar Entyvio (vedolizumab) and Keytruda (pembrolizumab) candidates as part of its pipeline, while Alvotech has...
Stay ahead of every shift in generics and biosimilars.
Generics Bulletin brings you the latest updates that matter for the off-patent industry.
Melinta Therapeutics has prevailed at the Federal Circuit in a patent dispute over its reformulated intravenous antibiotic Minocin, with the appeals court upholding both infringement and validity and leaving Nexus Pharmaceuticals barred from launching a generic until 2031.
